Author:
Smalley Richard V.,Goldstein David,Borden Ernest C.
Reference220 articles.
1. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J Am Med Assoc 1984; 252: 938–941.
2. Aderka D, Michalevicz R, Daniel Y, et al. Recombinant interferon alpha-C for advanced hairy cell leukemia. Cancer 1988; 61: 2207–2213.
3. Aderka D, Levo Y, Ramot B. Reduced production of tumor necrosis factor (TNF) by mononuclear cells of hairy cell leukemia patients and improvement following leukemia therapy. Cancer 1987; 60: 2208–2212.
4. Ahre A, Bjorkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high dose melphalanprednisone administration in the treatment of multiple myeloma. A randomized clinical trial from the myeloma group of central Sweden. Cancer Treat Rep 1984; 68: 1331–1338.
5. Ajani J, Rios AH, Ende K, et al. Phase I and II Studies of the combination of recombinant human interferon-alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Resp Modif 1989; 8: 14–46.